The Nigeria Football Federation (NFF) is reportedly expecting to return former Super Eagles coach Jose Peseiro, as they continue their search for a new head coach.
Peseiro previously led the national team for over two years, guiding them to a second-place finish in the 2023 Africa Cup of Nations.
Peseiro’s contract of the Portuguese tactician with the NFF expired in February 2024 after a series of unsuccessful negotiations primarily over salary demands.
Different reports also claimed that Jose Peseiro walked away from the negotiation because the NFF refused to accept his wage demands.
Hence, the NFF had to appoint his assistant coach, Finidi George who didn’t spend more than two months on the job before he resigned.
Finidi George who decided to walk away from the job after reports went viral that the NFF was planning to appoint a foreign technical adviser whom he would work under.
In over three weeks, the coaching seat of the Super Eagles has remained vacant ahead of the commencement of the 2025 AFCON qualifiers.
With the coaching position vacant, discussions are ongoing for Peseiro’s potential return, as stated by Gerald Baloyi of Vodia Sports International Management. This development comes ahead of the 2025 AFCON qualifiers scheduled to begin in September 2024.
Ronaldo’s Portugal Seal Confidence Boosting Win Over Nigeria
Cristiano Ronaldo has expressed confidence in Portugal’s readiness for the 2026 FIFA World Cup after the European side secured...
Our analysis of population based cancer registry data supports either a recent decline in the rate of mastectomy, or, among some groups, a shift from 2000 onward in surgical treatment toward mastectomy for early stage breast cancer priligy seratonin
can you get generic cytotec Professor Milla Santos and colleagues 10 intend to perform further follow up on these patients to assess the impact of anastrozole on clinical outcome, but in the meantime they point out that their data so far support previous reports of benefit associated with anastrozole as first line therapy in postmenopausal patients with advanced over tamoxifen, including its superiority over tamoxifen